Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: POZEN Clear all

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Diclofenac/Misoprostol; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Platelet Aggregation
Interventions: Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®); Drug
Lead sponsor: POZEN; Industry
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bunionectomy, Orthopedic Surgery
Interventions: Lornoxicam 8 mg, Lornoxicam 16 mg, Ketorolac 30 mg, Placebo; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Platelet Inhibition
Interventions: PN400, ASA, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: aspirin, omeprazole; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Volunteer
Interventions: celecoxib; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions: PN 200 tablets (500 mg naproxen and 20 mg omeprazole), Naproxen 500 mg tablets (PN 200 minus omeprazole); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Pompano Beach, Florida

Conditions: Aspirin-Associated Gastric Ulcers
Interventions: PA32540; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Headache (Migraine)
Interventions: Lornoxicam 8 mg, Lornoxicam 16 mg, Placebo; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Timeline: 2005 – 2006
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 20 more

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Arthritis
Interventions: PN400, Naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Migraine Headaches
Interventions: Sumatriptan and Naproxen sodium; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greensboro, North Carolina

Conditions: Gastric Ulcer
Interventions: PA32540, EC Aspirin 325; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Arthritis
Interventions: PN 400, EC naproxen plus EC esomeprazole, EC naproxen, EC esomeprazole; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: MT400; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: PN 200; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Migraine Headaches
Interventions: sumatriptan, naproxen sodium; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee

Conditions: Arthritis
Interventions: PN400; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Arthritis
Interventions: PN400, naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Migraine Headaches
Interventions: sumatriptan, naproxen sodium; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug · Other
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastric Ulcer
Interventions: PA32540, EC-Aspirin 325 mg; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin

Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations

The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months

A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels

Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches

Study Evaluating the Effect of Food on the Bioavailability of PN400 Components

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers